Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Dupixent is generally dosed every two or four weeks for AD. At the American Academy of Dermatology (AAD) congress in San Diego, data from STEAM-AD showed that amlitelimab achieved sustained ...

Dupixent (dupilumab) is tipped to be the market ... strong performance in clinical trials improving atopic dermatitis (AD) in moderate-to-severe patients, where it is the first systemic drug ...

“The anticipated sales of Dupixent for AD are projected to reach $6.2b in 2030, highlighting the significant rewards and substantial potential in this rapidly evolving market,” Maniatis added.

There must be people who have never seen the Jardiance commercial, but I’ll bet most of us can sing along with the song about “the little pill with the big story to tell.” This earworm is ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

Rinvoq's total estimated spending came in about $40 million behind Skyrizi's total last year, according to iSpot.TV, while Dupixent's total ... $223 million behind six ads—half in major ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold standard for AD, Sanofi has raised the bar for competitors in this space. However, Sanofi’s CEO has ...

Dupixent is the flagship drug of Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceutical Inc (NASDAQ:REGN). In the study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint ...